Search Results

1 - 10 of 1,610 items :

  • "cardiovascular disease" x
Clear All

References [1] Health Information Centre, Institute of Hygiene, Ministry of Health of The Republic of Lithuania, Causes of death 2017, Vilnius 2018. http://www.hi.lt/uploads/pdf/leidiniai/Statistikos/Mirties_priezastys/MPR_2017_isankstiniai.pdf . [2] WHO HFA Mortality database, 2009. [3] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease

ABBREVIATIONS ADP - adenosine-diphosphat; ACS - acute coronary syndrome; CAD - coronary artery disease; CHD - coronary heart disease; CV - cardiovascular; CVD - cardiovascular disease; DAPT - dual antiplatelet therapy; GI - gastrointestinal bleeding; MI - myocardial infarction; NSAIDs - non-steroid anti-inflammatory drugs; PAD - peripheral artery disease; PCI - percutaneous coronary intervention; RCT - randomized controlled trial; REFERENCES 1. Aleksandric S, Tomasevic M, Dobric M, Beleslin B, Tasic M. Antitrombocitna terapija u

References Labarthe DR. Epidemiology and prevention of cardiovascular diseases. A global challenge. Gaithersburg, Maryland: Aspen Publishers; 1998. Marmot M; Elliot PE. Coronary Heart Disease Epidemiology. From aetiology to public health. New York: Oxford University Press; 2005. Boice JD Jr. An affair of the heart. J Natl Cancer Inst 2007;99(3):186-7. Mabuchi K. Overview of studies of long-term cardiovascular effects in humans. Radiat Res 2007;167:348-9. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence

JD, Straus DC, Madison RA, Hooper D. (2013). Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins 5 : 605-615. Brown VJ. (2008). Dioxin exposure and cardiovascular disease: An analysis of association. Environ Health Perspect 116 (11): A491. Brunekreef B, Beelen R, Hoek G, Schouten L, Bausch-Goldbohm S, Fischer P, Armstrong B, Hughes E, Jerrett M, van den Brandt P. (2009). Effects of longterm exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study. Res Rep Health Eff Inst

REFERENCES 1. Nichols M, Townsend N, Scarborough P, et al. European cardiovascular disease statistics 2012 edition. Sophia Antipolis: European Heart Network; 2012. 2. Cierniak-Piotrowska M, Marciniak G, Stańczak J. Statystyka zgonów i umieralności z powodu chorób układu krążenia. In: Z. Strzelecki, J. Szymborski (ed). Zachorowalność i umieralność na choroby układu krążenia a sytuacja demograficzna Polski. Warszawa: Rządowa Rada Ludnościowa; 2015. 3. Piskorz A, Brzostek T, Piórecka B. Występowanie wybranych czynników ryzyka chorób układu krążenia w grupie kobiet w

References 1. Goodarzi M, Carmina E, Azziz R. DHEA, DHEAS and PCOS. J Ster Bioch 2015; 145: 213–25. 2. World Health Organisation, Global Health Observatory data, Mortality and morbidity, Cardiovascular diseases [04.09.2016.], http://www.who.int/gho/ncd/mortality_morbidity/cvd/en/ . 3. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997; 126: 32–5. 4. Legro RS. Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association? End

of myocardial infarction, 89 , 941–1001. Imamura, F., Lemaitre, R. N., King, I. B., Song, X. (2012). Novel circulating fatty acid patterns and risk of cardiovascular disease: The cardiovascular health study. Amer. J. Clin. Nutr. , 96 (6), 1252–1261. Iqbal, M. P. (2014). Trans fatty acids: A risk factor for cardiovascular disease. Pakistan J. Med. Sci. , 30 (1), 194–197. Jasti, S., Kovacs, S. (2010). Use of trans fat information on food labels and its determinants in a multiethnic college student population. J. Nutr. Educ. Behav ., 42 (5), 307–314. Krettek

risk factors in the WHO MONICA project. Int J Epidemiol 2001;30 (Suppl 1):S35-40. Antikainen RL, Moltchanov VA, Chukwuma C Sr, Kuulasmaa KA, Marques-Vidal PM, Sans S, et al. WHO MONICA Project. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006;13:13-29. Carnethon M, Whitsel LP, Franklin BA, Kris-Etherton P, Milani R, Pratt CA, et al. Worksite Wellness Programs for Cardiovascular Disease Prevenmtion: A Policy Statement from the American Heart Associatin. Circulation 2009

1998; 338: 1650-6. 5. Veigas NM, Dharmalingam M, Rani Marcus S. Oxidative stress in obesity and metabolic syndrome in Asian Indians. Journal of Medical Biochemistry 2011; 30: 115-20. 6. Palinski W, Napoli C. The fetal origins of atherosclerosis: maternal hypercholesterolemia and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to athe - rogenesis. The FASEB Journal 2002; 16: 1348-60. 7. De Backer G, Ambrosioni E, Borch-Johensen K, et al. European guidelines on cardiovascular disease prevention

R eferences 1. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 163: 33–40, 2003. 2. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health 88: 765–770, 1998. 3. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 95